Spine Biologics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027

Spine Biologics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027

The global spine biologics market size reached US$ 1.9 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 2.5 Billion by 2027, exhibiting a growth rate (CAGR) of 4.32% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

Spine biologics are materials that alter the surrounding environment through active cellular processes. They promote growth and differentiation and aid in the repair and healing of an injury. They also reduce the frequency of primary or additional surgical procedures and decrease the disruption of soft tissue. At present, a wide variety of spine biologics are used as an alternative to conventional treatments. For instance, pedicle screws and rods find application in a spine fusion procedure to provide spinal stabilization, thereby promoting healing. Moreover, continuous advancements are promoting the repair and regeneration of cartilaginous and bony structures.

Spine Biologics Market Trends:
Spine fusion is utilized as a tool in the treatment of spine trauma, tumors, and degenerative disorders. However, its poor outcomes can lead to serious complications among patients. This, in confluence with a significant increase in the number of individuals with acute and chronic conditions represents one of the key factors positively influencing the use of spine biologics around the world. Spine biologics impact fusion at the cellular level, which helps achieve successful arthrodesis in the treatment of symptomatic deformity or instability. Moreover, there is a rise in the geriatric population globally, which is more susceptible to musculoskeletal conditions. This, along with the growing prevalence of orthopedic conditions, is catalyzing the demand for spine biologics worldwide. Apart from this, the escalating demand for non-surgical procedures is encouraging the use of spinal biologics in minimally invasive lumbar surgeries. Spine biologics are also gaining traction as a replacement for metal hardware and in individual natural bone grafts or allografts. Furthermore, the growing access to healthcare services on account of inflating income levels is contributing to market growth.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global spine biologics market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product, surgery type and end user.

Breakup by Product:

Spinal Allografts
Machined Bones Allograft
Demineralized Bone Matrix
Bone Graft Substitutes
Bone Morphogenetic Proteins
Synthetic Bone Grafts
Cell Based Matrix

Breakup by Surgery Type:

Open Spine Surgery
Minimally Invasive Spine Surgery

Breakup by End User:

Hospitals
Ambulatory Care Centers
Spinal Surgery Centers
Orthopedic Clinics
Others

Breakup by Region:

North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Arthrex Inc, Alphatec Holdings Inc., Exactech Inc, Johnson & Johnson, Medtronic plc, NuVasive Inc, Orthofix Medical Inc., Stryker Corporation, Wright Medical Group N.V. and Zimmer Biomet.

Key Questions Answered in This Report:
How has the global spine biologics market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global spine biologics market?
What are the key regional markets?
What is the breakup of the market based on the product?
What is the breakup of the market based on the surgery type?
What is the breakup of the market based on the end user?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global spine biologics market and who are the key players?
What is the degree of competition in the industry?